Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Gemtuzumab Ozogamicin Acute Myeloid Leukemia By FAB Classification	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Adult Pure Erythroid Leukemia	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Core Binding Factor Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	CCC (53)
Gemtuzumab Ozogamicin Fit Patients	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Gemtuzumab Ozogamicin FLT3 Internal Tandem Duplication Positive	First Affiliated Hospital of Zhejiang University	P2	CCC (53)
Gemtuzumab Ozogamicin Myelodysplastic Syndrome With Excess Blasts	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Myeloid Sarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Myeloproliferative Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Philadelphia Chromosome Positive	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Untreated Adult Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	CCC (53)
hlx43 Triple-Negative Breast Carcinoma	Shanghai Henlius Biotech	P2	CCC (53)
hlx43 Hepatocellular Carcinoma	Shanghai Henlius Biotech	P2	CCC (53)
hlx43 Breast Tumor Luminal A Or B	Shanghai Henlius Biotech	P2	CCC (53)
Ifinatamab Deruxtecan Recurrent or Metastatic Solid Tumors	Daiichi Sankyo	P2	CCC (53)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Hepatocellular Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (53)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Recurrent Glioblastoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (53)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Renal Cell Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (53)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative Lung Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (53)
Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated to auristatin E Breast Carcinoma	Shanghai Miracogen Inc.	P2	CCC (53)
Immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody; conjugated to auristatin E Non-Small Cell Lung Carcinoma	Shanghai Miracogen Inc.	P2	CCC (53)
Inotuzumab Ozogamicin Blinatumomab	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Inotuzumab Ozogamicin Inotuzumab Ozogamicin	The First Affiliated Hospital of Soochow University	P2	CCC (53)

Showing 351 to 375 of 1,027 assets

PreviousPage 15 of 42Next